E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Osteonecrosis of the Femoral Head |
Osteonecrosis de la cabeza femoral |
|
E.1.1.1 | Medical condition in easily understood language |
Osteonecrosis of the Femoral Head |
Osteonecrosis de la cabeza femoral |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10031264 |
E.1.2 | Term | Osteonecrosis |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10028395 |
E.1.2 | Term | Musculoskeletal and connective tissue disorders |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003860 |
E.1.2 | Term | Avascular necrosis femoral head |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety, feasibility and preliminary efficacy of bone marrow-derived allogenic MSCs use in the treatment of osteonecrosis of femoral head (ONFH), with placement at necrosis site |
Evaluar la seguridad, viabilidad y eficacia preliminar del uso de células madre mesenquimales de médula ósea (CMM) alogénica en el tratamiento de osteonecrosis de la cabeza femoral (ONCF), con administración en el lugar de la necrosis. |
|
E.2.2 | Secondary objectives of the trial |
To obtain bone regeneration maintaining head sphericity and/or avoiding progression of femoral head collapse, without increasing the complication rate, in femoral heads with symptomatic osteonecrosis of femoral head (ONFH) |
Obtener regeneración ósea, manteniendo la esfericidad y/o evitando la progresión del colapso de la cabeza femoral, sin aumentar la tasa de complicaciones, en osteonecrosis de la cabeza femoral sintomáticas. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age: 8 to 55, both sexes - Patients having received allogeneic haematological stem cell transplant (HSCT), due to hematologic diseases, in remission. The patient may be or have been under immunosupression. - Osteonecrosis of the femoral head (MRI diagnosis): Ficat and Arlet 0, 1, 2 or 3 or ARCO stages 0, I, IIA, IIB, IIC, IIIA, IIIB, IIIC or Steinberg stages 0, I, II, III. - Able to provide informed consent, and signed informed consent (by themselves or legal representative) - Medical health care coverage - Able to understand and accept the study constraints (by themselves or legal representative) |
- Edad: 8 a 55 años, ambos sexos - Pacientes receptores de un trasplante alogénico de células madre hematopoyéticas, en remisión. El pacientes pueda estar con/sin tratamiento inmunosupresor - Osteonecrosis de la cabeza femoral (diagnostico por RMN): Ficat y Arlet 0, 1, 2 o 3; o estadios ARCO 0, I, IIA, IIB, IIC, IIIA, IIB, IIIC; o estadios Steinberg 0, I, II, III. - Capacidad de proporcionar consentimiento informado y firmarlo (por el paciente o su representante legal) - Disponer de cobertura sanitaria - Entender y aceptar los requisitos del estudio (el paciente o su representante legal) |
|
E.4 | Principal exclusion criteria |
- Disease in relapse - Active infection of any location and aetiology - Surgical contraindication of any cause - Pregnancy, breastfeeding women and women who are of childbearing age and not practicing adequate birth control. - Stage 4 (Ficat and Arlet) or IV and above (Steinberg) or ARCO IV, with severe femoral head osteonecrosis associated to acetabular changes, primarily based on diagnosis by imaging (X-Rays, MRI) - Flattening or collapse of the femoral head (Steinberg stage IV) or articular cartilage collapse at the time of core decompression surgery - Any tumour infiltration of the femoral head and/or neck - Other tumour infiltration with short-term life risk - Stress or pathological fracture of the femoral neck - Traumatic osteonecrosis - Non-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, monostotic or polyostotic fibrous dysplasia, McCune-Albright syndrome and osteopetrosis) - Any active bisphosphonate treatment (or 3 months before the trial, except in case they are used in the treatment of an acute disorder that requires prompt management, e.g., severe hypercalcemia, severe bone pain). - Any evidence of HIV, Hepatitis B or Hepatitis C infection (confirmed by serology or PCR) - Known allergies to products involved in the production process of MSC - History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening and/or history of illicit drug use - MRI incompatible internal devices (pacemakers, aneurysm clips, etc.) - Impossibility to meet at the appointments for the clinical follow up |
- Recaída de la enfermedad hematológica. - Infección activa, en cualquier localización y de cualquier etiología. - Contraindicación quirúrgica de cualquier tipo. - Embarazo, lactancia o mujeres en edad fértil que no practiquen un método anticonceptivo adecuado. - Estadio 4 (Ficat and Arlet) o IV y superior (Steinberg) o ARCO IV, con osteonecrosis femoral grave asociada a cambios acetabulares, basado principalmente en diagnóstico radiológico (radiografía, RMN). - Aplanamiento o colapso de la cabeza femoral (estadio Steinberg IV) o colapso del cartílago articular en el momento de la cirugía de descompresión. - Infiltración tumoral del cuello o la cabeza femorales. - Otras infiltraciones tumorales con riesgo vital a corto plazo. - Fractura patológica o por estrés del cuello femoral. - Osteonecrosis traumática. - Enfermedades metabólicas óseas distintas a la osteonecrosis (en especial enfermedad de Paget ósea, osteogénesis imperfecta, hiperparatiroidismo primario, displasia fibrosa (afectación mono- o poliósea), síndrome de McCune-Albright y osteopetrosis). - Tratamiento con bifosfonatos actual o en los 3 meses previos a la inclusión en el ensayo (excepto si se han usado para el tratamiento de alteraciones agudas que requieren un manejo clínico inmediato, por ejemplo hipercalcemia grave o dolor óseo grave). - Infección por VIH, hepatitis B o C, confirmadas por serología o PCR. - Antecedentes de alergias a productos involucrados en el proceso de produccion de CMMs. - Antecedentes de consumo habitual de alcohool excediendo 2 bebidas/día (1 bebida= 150mL de vino o 360mL de cerveza o 45mL de licor destilado) en los 6 meses previos al screening y/o antecedente de uso de drogas de abuso. - Ser portador de un dispositivo interno no compatible con RMN (marcapasos, clips para aneurismas, etc.). - Imposibilidad de acudir a las citas médicas para el seguimiento. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Early local complication rate, as the percentage of patients with local complications within 12 weeks after surgery - Global complication rate, as the percentage of patients with local or general complications at 52 weeks. |
- Tasa de complicaciones locales tempranas, definidas como el porcentaje de pacientes con complicaciones locales en las 12 semanas después de la cirugía. - Tasa de complicaciones globales, como el porcentaje de pacientes con complicaciones locales o generales a las 52 semanas después de la cirugía |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 and 52 weeks |
12 y 52 semanas |
|
E.5.2 | Secondary end point(s) |
- Local and general complication rate at 12, 24 and 104 weeks - Rate of bone healing, as the percentage of patients without clinical and radiological progression at 52 weeks. - Rate of patients with no clinical progression to the next stage (defined as 0 to 1, 1 to 2, 2 to 3 and 3 to 4) at 52 weeks, particularly assessing the progression to femoral head flattening (Steinberg IV and over).. - Rate of patients with no radiological or MRI progression at 6 weeks (X-ray), 12 weeks (X-ray, MRI), 24 weeks X-ray), and 52 weeks (X-ray, MRI). - Amount of necrotic bone in the femoral head at 12 weeks and 52 weeks in MRI, compared with preoperative status. - Changes in serum levels of bone turnover markers (in a centralized laboratory) at 12, 24 and 52 weeks after treatment, compared with preoperative levels. - Pain assessed by Likert Scale (1 to 10) at 12, 24 and 52 weeks |
- Tasa de complicaciones locales y generales a las semanas 12, 24 y 104. - Tasa de regeneración ósea, definida como el porcentaje de pacientes sin progresión clínica ni radiológica a las 52 semanas. - Tasa de pacientes sin progresión clínica al siguiente estadio (definida como progresión de 0 a 1, 1 a 2, 2 a 3, 3 a 4) a las 52 semanas, en especial valorando la progresión a aplanamiento de la cabeza femoral (Steinberg IV o superior). - Tasa de pacientes sin progresión radiológica o en RMN a las 6 semanas (radiografía), 12 semanas (radiografía, RMN), 24 semanas (radiografía) y 52 semanas (radiografía, RMN). - Cantidad de hueso necrótico en la cabeza femoral a las 12 y 52 semanas mediante RMN, en comparación con el estado pre-operatorio. - Cambios en los niveles séricos de marcadores óseos a las 12, 24 y 52 semanas post-tratamiento, con respecto a los niveles pre-cirugía. - Evaluación del dolor, mediante la escala de Likert (de 1 a 10), a las 12 y 52 semanas, en comparación con la situación pre-cirugía (visita 2, día anterior a la cirugía). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12, 24, 52 or 104 weeks |
12, 24, 52 o 104 semanas |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |